The Co-Investor Question: Why Capital Alone Does Not Build Biotech Winners

In a recent dialogue with Károly Szántó and Thijmen Meijer, we returned to a question that repeatedly surfaces in early-stage biotech, often too late.

In early-stage biotech, we often speak about science, capital, regulation, and timing. We analyze markets and debate valuations. We obsess over technical risk and exit multiples.

Yet in my experience, one question determines the trajectory of a company long before Phase II data or acquisition talks:

Who is sitting next to you on the cap table?

Not how much money they bring.
Not how recognizable their logo is.
But who they are, how they think, and whether they are aligned with execution.

In biotech and MedTech, the co-investor question is not peripheral. It is structural. It defines how decisions are made under uncertainty, how risk is absorbed, and how resilience is built when reality diverges from the spreadsheet.

After two decades in clinical research and venture investing across Europe and Asia, I have come to a simple conclusion: capital without alignment is noise. Capital with aligned execution is leverage.

Beyond Investor “Types”

It is tempting to categorize investors into clean boxes: angels, venture capital, corporate venture, family offices, and high-net-worth individuals. These labels are useful for conference panels. They are less useful in practice.

The relevant distinction is not type. It is a value proposition.

There are investors who bring capital.
There are investors who bring expertise.
There are investors who bring distribution channels or regulatory insight.
And there are investors who bring patience.

The question is whether their strengths complement the stage and risk profile of the company.

In our model, we invest not only money but also time, operational support, and clinical oversight. We put skin in the game. If a trial design is flawed, if enrollment stalls, if regulatory positioning is weak, we feel the consequences alongside the founders and the co-investors.

That shared exposure changes the dynamic. It creates discipline.

Without it, capital becomes detached from execution. And detached capital often amplifies risk rather than mitigating it.

Two Archetypes That Matter

In early-stage biotech, I see two broad investor profiles that can create real value when properly aligned.

The first group is thesis-driven but not deeply specialized. These investors may focus on deep tech or healthcare broadly. They understand innovation, but they may not possess decades of experience in clinical development or regulatory navigation.

For them, specialization is not a weakness. It becomes a partnership opportunity. When combined with a clinical operator who can validate trial design, de-risk execution, and anticipate regulatory inflection points, the equation strengthens.

The second group is deeply embedded in biotech or MedTech. They know the terrain. They understand how fragile early clinical data can be. They appreciate that a promising preclinical asset can be destroyed by poor protocol design or weak site management.

With these investors, the conversation moves quickly from vision to execution. The dialogue shifts toward enrollment strategy, endpoint selection, biomarker validation, and reimbursement pathways. Synergies tend to be strongest at this level, particularly when both sides respect the operational complexity of clinical development.

In both cases, alignment is less about enthusiasm and more about shared discipline.

The Role of Angels and Early Believers

At the pre-seed and seed stage, angel investors still play a meaningful role. In many regions, particularly in Central and Eastern Europe, angels are often the first to back a scientific founder.

The best angels are hands-on. They open doors, challenge assumptions, and provide emotional stability in moments of doubt.

Early-stage biotech is not a financial spreadsheet exercise. It is an endurance test. Founders navigate scientific uncertainty, regulatory friction, and capital scarcity simultaneously. In that environment, experienced angels can be catalytic.

But again, alignment is decisive. Angels who expect rapid liquidity in a domain where development cycles can span a decade are structurally misaligned. Patience must match biology.

Corporate Venture Capital: Strategic Signal or Strategic Constraint?

Corporate venture capital from pharmaceutical companies offers a distinct value dimension. It provides strategic insight into how large pharma evaluates assets, structures partnerships, and determines what makes a company acquisition-ready.

For a biotech founder, that insight can be transformative. Understanding how to build toward a strategic exit five to seven years down the line requires more than scientific excellence. It requires architectural thinking.

Yet corporate capital also introduces complexity. Strategic investors may have priorities that diverge from the startup’s long-term optionality. The governance structure must be designed carefully to avoid constraining future flexibility.

Corporate capital can be powerful. It must be handled deliberately.

The Distinct Logic of Family Offices

Family offices deserve separate attention. In markets such as Singapore, where thousands of family offices operate within a small population, they have become significant players in private healthcare investment.

Unlike traditional venture funds, many family offices are values-driven. Often their investment focus is shaped by personal history: a family member affected by cancer, neurodegenerative disease, or rare disorders. Their capital is frequently motivated by impact and legacy rather than quarterly performance metrics.

The engagement model is fundamentally different.

Family offices rarely respond to cold outreach. They prioritize relationships over transactions. Trust precedes term sheets. Conversations begin with shared values before they turn to valuation.

Their due diligence can be rigorous, but it is rarely mechanical. It includes an assessment of character and long-term alignment. In that sense, they are often described as “patient capital.”

However, patience does not mean naivety. Many family offices that attempted to operate as de facto venture funds discovered how complex portfolio construction and governance truly are. Increasingly, sophisticated family offices are choosing to invest as limited partners in specialized funds or to co-invest alongside experienced operators rather than building standalone venture infrastructure.

For biotech founders, this shift opens an opportunity. But it demands authenticity and time.

The Misunderstood High-Net-Worth Investor

There is another category that frequently appears promising but often proves misaligned: successful high-net-worth individuals from unrelated sectors.

I have met highly accomplished real estate or industrial entrepreneurs who describe themselves as experienced investors. Yet when confronted with the structural logic of venture capital, dilution dynamics, portfolio theory, and the asymmetry of biotech risk, the conversation often stalls.

If an investor cannot internalize why owning 15 percent of a transformative asset can be more valuable than 100 percent of a stagnant one, structural misalignment follows.

It is not a question of intelligence. It is a question of familiarity with the asset class.

In such cases, honesty is essential. Shared ambition does not guarantee compatible operating models. Forcing alignment where it does not exist rarely ends well.

A Structural Shift in Venture Capital

The broader venture ecosystem is evolving.

Large, established funds manage billions and collect substantial management fees. As assets under management increase, the incentive structure can drift. Fee income becomes material relative to performance income. The urgency to generate outsized returns may dilute.

Meanwhile, data increasingly suggest that smaller, specialized funds, often with assets of €50–80 million or less, generate superior returns in certain segments. Their survival depends on performance. They cannot rely on scale to compensate for mediocrity.

For limited partners, this trend is visible. Emerging managers with deep domain expertise are attracting attention. In biotech, industry-agnostic capital is losing relevance. Vertical specialization is no longer optional.

This shift reinforces a broader thesis: operational competence and domain focus are becoming decisive differentiators.

Execution as the Missing Layer

Across investor categories, one theme recurs: execution.

Clinical development is not an abstract process. It is a sequence of thousands of micro-decisions that determine whether a promising molecule becomes a therapy or a failed experiment.

Poor study design.
Inconsistent data management.
Misaligned endpoints.
Recruitment delays.
Regulatory missteps.

These are not theoretical risks. They are common failure points.

Investors who understand this and align around structured risk mitigation create disproportionate value. Those who underestimate it often learn the lesson late.

In our own work, de-risking is not a marketing slogan. It is a disciplined, operational practice embedded in trial design, site selection, monitoring strategy, and the sequencing of capital deployment.

The co-investor question, therefore, becomes a test of whether capital respects process.

The Long View

Biotech does not reward impatience. It rewards coherence.

Founders must ask themselves not only who will write the first check, but who will remain constructive when timelines shift, when data surprises, when regulatory feedback demands iteration.

Investors must ask themselves whether they are prepared to engage with the complexity of science, rather than imposing financial templates unsuited to biological reality.

The right co-investor is not defined by brand or fund size. The right co-investor is defined by alignment in values, in time horizon, and in operational rigor.

In an industry where failure rates remain high and development costs escalate, capital is abundant in some cycles and scarce in others. Alignment, however, is always scarce.

And in biotech, alignment is not a luxury.

It is the difference between potential and outcome.